Osteoporosis therapeutics - Warner Chilcott
Latest Information Update: 18 May 2020
At a glance
- Originator Warner Chilcott
- Developer AbbVie
- Class Bisphosphonates; Small molecules
- Mechanism of Action Bone resorption factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Postmenopausal-osteoporosis in USA
- 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc